The Danish National Center for Ethics has November 2nd, 2022, approved the un-blinded phase I clinical trial with dose-titrating of allogeneic adipose-derived mesenchymal stem cells (ASCs) for treatment of children with autism.
The project is a collaboration between Cell2Cure, Aalborg University, Aalborg University Hospital, Hvidovre Hospital, and Endeavour Cells ApS, who holds the sublicense from Cell2Cure for this indication.
The participants will be enrolled and treated at Aalborg University Hospital.
Endeavour Cells will financially sponsor the trial, but Cell2Cure will have the role as clinical sponsor.
It is expected that the trial will be ready to enroll the first participant early 2023.